These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Liu Y; Chen X; Han W; Zhang Y Drugs Today (Barc); 2017 Nov; 53(11):597-608. PubMed ID: 29451276 [TBL] [Abstract][Full Text] [Related]
6. Tracing the Path of CAR T Cells. Cancer Discov; 2017 Apr; 7(4):OF5. PubMed ID: 28193777 [TBL] [Abstract][Full Text] [Related]
7. [The CAR-T cells are here]. Croizier C; Douge A; Bay JO; Lemal R Bull Cancer; 2018 Sep; 105(9):743-745. PubMed ID: 30119830 [TBL] [Abstract][Full Text] [Related]
8. Cellular Immunotherapy in B-Cell Malignancy. Schwarzbich MA; Witzens-Harig M Oncol Res Treat; 2017; 40(11):674-681. PubMed ID: 29065420 [TBL] [Abstract][Full Text] [Related]
9. Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia. Jin CH; Xia J; Rafiq S; Huang X; Hu Z; Zhou X; Brentjens RJ; Yang YG EBioMedicine; 2019 Jan; 39():173-181. PubMed ID: 30579863 [TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. Maus MV; Levine BL Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942 [TBL] [Abstract][Full Text] [Related]
12. Overcoming Challenges in CAR T-cell Product CGMP Release. Quintarelli C; Locatelli F; Caruana I; De Angelis B Mol Ther; 2016 May; 24(5):845-6. PubMed ID: 27198849 [No Abstract] [Full Text] [Related]
13. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369 [TBL] [Abstract][Full Text] [Related]
14. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies. Daniyan AF; Brentjens RJ J Leukoc Biol; 2016 Dec; 100(6):1255-1264. PubMed ID: 27789538 [TBL] [Abstract][Full Text] [Related]
15. First approval in sight for Novartis' CAR-T therapy after panel vote. Sheridan C Nat Biotechnol; 2017 Aug; 35(8):691-693. PubMed ID: 28787408 [No Abstract] [Full Text] [Related]
16. Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials. Xu XJ; Zhao HZ; Tang YM Leuk Lymphoma; 2013 Feb; 54(2):255-60. PubMed ID: 22897728 [TBL] [Abstract][Full Text] [Related]
17. Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy. Rosenbaum L N Engl J Med; 2017 Oct; 377(14):1313-1315. PubMed ID: 28902570 [No Abstract] [Full Text] [Related]
18. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300 [TBL] [Abstract][Full Text] [Related]
19. CARTs to the rescue: therapeutic potential of chimeric antigen receptor T-cells in patients with B-cell malignancies. Tam CS Leuk Lymphoma; 2013 Feb; 54(2):215-6. PubMed ID: 22950939 [No Abstract] [Full Text] [Related]
20. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis. Zhou H; Luo Y; Zhu S; Wang X; Zhao Y; Ou X; Zhang T; Ma X BMC Cancer; 2018 Sep; 18(1):929. PubMed ID: 30257649 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]